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Edited by Masayuki MiyasakaAbstract Solamargine (SM), isolated from Solanum incanum
herb, displayed a superior cytotoxicity in four human lung cancer
cell lines. The half-inhibitory concentrations (IC50), of the cell
viability assay for H441, H520, H661 and H69 cells were 3, 6.7,
7.2 and 5.8 lM, respectively. SM-induced apoptosis of these
cells by PS externalization in a dose-dependent manner and
increased sub-G1 fraction were observed. Quenching of the
expression of tumor necrosis factor receptors (TNFRs) during
the progress of human lung carcinogenesis has been previously
reported. SM may induce cell apoptosis via modulating the
expression of TNFRs and their subsequent TRADD/FADD
signal cascades. Subsequently, SM treatment increased the
binding activities of TNF-a and TNF-b to the lung cancers, and
the intrinsic TNFs-resistant cancer cells became susceptible to
TNF-a and -b. In addition, SM caused release of cytochrome c,
downregulation of anti-apoptotic Bcl-2 and Bcl-xL, increase of
caspase-3 activity, and DNA fragmentation. Thus, SM could
modulate the expressions of TNFRs and Bcl-2, and might be a
potential anticancer agent for TNFs and Bcl-2 related resistance
of human lung cancer cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis1. Introduction
Lung cancers can be subdivided into two groups, small
cells lung carcinoma (SCLC) and non-small cell lung carci-
noma (NSCLC), according to their histological features.
SCLC is usually responsive to chemotherapy, whereas relapse
is inevitable and long-term survival is rare. NSCLC is
characterized by both high incidence and lethality, with ﬁve-* Corresponding author. Present address: 26, Lane 31, Sec. 1, Huan
Dong Rd., Sinshih, Tainan County, Tainan 744, Taiwan, ROC. Fax:
+886-7-349-7685.
E-mail address: kuokw@kmu.edu.tw (K.-W. Kuo).
Abbreviations: SM, solamargine; PS, phosphatidylserine; TNFRs,
tumor necrosis factor receptors; TNF, tumor necrosis factor; TRADD,
TNFR-1-associated death domain; FADD, Fas-associated death
domain; TRAIL, tumor necrosis factor-related apoptosis-inducing
ligand; PBS, phosphate-buﬀered saline; SDS–PAGE, sodium
dodecyl sulfate–polyacrylamide gel electrophoresis; MTS, [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo phenyl)-
2H-tetrazolium]
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.09.064year-survival rate accounting for less than 10% of the cases
[1]. The currently available chemotherapeutic treatment for
human lung cancers is disappointed. The poor prognosis of
lung cancers may be partially based on the pronounced re-
sistance to chemotherapeutic drugs that is present intrinsi-
cally in most NSCLC and is also acquired during the
treatment of initially drug-sensitive SCLC [2]. The underlying
mechanism of cellular resistance remains rather obscure.
Apart from classical drug resistance mechanisms, the failure
of tumor cells to undergo apoptosis also plays an important
role in drug resistance. Mutations and defects in the apop-
totic pathway are, therefore, additional factors that deter-
mine drug resistance, and the Bcl-2 family member is one of
important factors in this pathway in lung cancer [3]. Ad-
vanced search for more eﬀective agents or combination
therapy for treating lung cancers is essential. Thus, deﬁning
the molecular determinants of sensitivity or resistance to
chemotherapy would have important implications for the
treatment of lung cancers.
Apoptosis is considered to be the major process responsible
for cell death in various physiological events and has become a
focus of interest in oncology. Most anticancer drugs have been
shown to cause cell death by inducing apoptosis [4]. Ability to
manipulate the machinery of cell death is an obvious goal of
medical research and eﬀect on regulation of apoptosis might
lead to new possibilities for cancer treatment. Tumor necrosis
factors (TNFs) have emerged as one of the many host-derived
mediators that, either alone or in combination, appear to
mediate both antiproliferative and tumorigenic eﬀects in ma-
lignant tumors. The TNF family is comprised of two cyto-
kines, TNF-a (cachectin) and TNF-b (lymphotoxin-a), which
are secreted by a wide variety of cells [5]. TNFs bind with
nearly identical aﬃnities to distinct tumor necrosis factor re-
ceptors (TNFRs), TNFR-I and -II. TNFR-I and -II have been
reported as vital mediators of TNF-a in triggering apoptosis
[6]. TNFR-I is functional in almost every cell type and can
independently transmit most biological activities [7]. The ex-
pression of TNFR-II can strongly induce TNF-a mediated
cytotoxicity through TNFR-I in lung cancer cells [8]. Although
normal lung cells express TNFR-I and -II, loss or downregu-
lation of TNFRs occurs during the progression of lung cancers
[9,10]. It had also been reported that retinoic acid would
modulate the expression of TNFR-I and TNFR-II in lung
cancer cells and sensitize cells to TNF-induced apoptosis [11].
Since inherent and acquired drug resistance is commonly
present in human lung cancers, the downregulation of TNFRsblished by Elsevier B.V. All rights reserved.
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may consequently cause drug resistance.
Solamargine (SM), a steroidal glycoalkaloid, has been iso-
lated from the fruits of Solanum incanum [12] and its structure
has been determined [13]. Like other steroidal molecules, SM
exerts its action by penetrating the cell membrane by simple
diﬀusion. SM inhibits the growth of human tumor cells, e.g.,
colon (HT-29 and HCT-15), prostate (LNCaP and PC-3),
breast (T47D and MDA-MB-231), human hepatoma (PLC/
PRF/5) and JTC-26 cells [14]. Previous experiments had shown
that SM could trigger gene expression of TNFRs in Hep 3B
cells, which might lead to apoptosis [15–17]. However, the
detailed anti-neoplastic mechanism of SM remains to be in-
vestigated in the drug-resistant lung cancers. In this paper, the
eﬀects of SM in human non-small cell lung cancers (H441,
H520 and H661) and small cell lung cancer (H69) cells were
characterized. These results revealed a novel gene modulation
of SM in overexpressed Bcl-2 and TNFs-resistant cancer cells,
and might elicit the anticancer potential of SM against human
lung cancers.2. Materials and methods
2.1. Drugs
Drugs were provided as pure substances. SM (isolated from berries
of Solanum khasianum Clarke) and etoposide (Bristol-Myers Squibb,
Syracuse, NY) were diluted in DMSO. Cisplatin (Bristol-Myers
Squibb, Woerden, The Netherlands) and gemcitabine (Eli Lilly Re-
search Laboratories, Indianapolis, IN) were diluted in phosphate-
buﬀered saline (PBS), and paclitaxel (Bristol-Myers Squibb, Syracuse,
NY) was diluted in ethanol. The drugs were freshly diluted to the ﬁnal
concentration in culture medium before experiment.
2.2. Cell lines and cultures
Human adenocarcinoma (H441), squamous cell lung carcinoma
(H520), large cell lung cancer (H661) and small cell lung cancer (H69)
were purchased from the American Type Culture Collection (Rock-
ville, Maryland). The cells were cultured at 37 C in a humidiﬁed at-
mosphere of carbon dioxide–air (5:95). The culture medium consisted
of RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (Hazelton Products,
Denver, PA), 100 lg/ml streptomycin and 100 U/ml penicillin.
2.3. Growth-inhibition assay
A 100 ll suspension of 1 104 cells was added to each well of ﬂat-
bottomed, 96-well multi-dishes (Corning, Elmira, NY). After 24 h,
various concentrations of the drugs (SM, cisplatin, gemcitabine, pac-
litaxel and etoposide) were added to the cells for 16 h. To determine the
combined eﬀects of TNFs and SM, cells were pre-incubated with or
without SM for 2 h before TNFs were added. A colorimetric tetra-
zolium [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfo phenyl)-2H-tetrazolium] (MTS) method was utilized to
determine cell viability according to the manufacturer’s procedures
(CellTiter 96TM AQ, Promega, Madison). The absorbance at 490 nm
(A490) was measured with an automated plate reader (Dydatech, Al-
exandria, VA). Absorbance values were expressed as a percentage of
untreated controls, and concentrations resulting in cell growth inhi-
bition of 50% (IC50) and 80% (IC80) were calculated. All determina-
tions were performed in triplicate and statistically analyzed by
Student’s t test.
2.4. Flow cytometry of SM-treated cells
Spontaneous cell death in the absence of SM was less than 10%.
Detection of phosphatidylserine (PS) on the outer leaﬂet of SM (IC50
and IC80 concentration)-treated cells was carried out with annexin-
V-FLUOS method (Boehringer Mannheim, Mannheim, Germany).
Besides, sub-G1 DNA content refers to the portion of apoptotic cells.
The sub-G1 analysis of SM (IC50 and IC80)-induced apoptosis was
determined by ﬂow cytometry analysis of PI-stained nuclei. Brieﬂy, thecells were trypsinized and resuspended in the original supernatant to
ensure that both attached and non-attached cells were analyzed.
Fluorescein isothiocyanate (FITC)-conjugated annexin-V and/or pro-
pidium iodide (PI; a ﬂuorescent DNA intercalating dye) were added,
and 10 000 cells were analyzed by Epics Elite ESP apparatus. Quan-
titative measurements were done with WinMDI software.
2.5. Determination of change of gene expression by RT-PCR
Cellular RNA was isolated from IC50 concentration of SM-treated
and untreated cells by guanidinium thiocyanate/cesium chloride
gradient ultracentrifugation method. All RNA preparations were
treated with DNase and stored in liquid nitrogen prior to use.
Reverse transcriptase of moloney murine leukemia virus was used to
prepare cDNA (Clontech, Palo Alto, CA). The primer sequences for
detecting TNFR-I, TNFR-II, TNFR-1-associated death domain
(TRADD), Fas-associated death domain (FADD), Bcl-xL and Bcl-2
were designed as previously report [18–20]. Diﬀerential gene was
determined by normalizing its expression against b-actin and
GAPDH, and by 2% agarose staining with 0.5 lg/ml ethidium
bromide.
2.6. Fluorescent immunocytochemistry
Cells were treated with or without IC50 concentration of SM for 16
h. Anti-human TNFR-I and TNFR-II monoclonal antibodies (10 lg/
ml) (Genzyme, Cambridge, MA) or human recombinant TNF-a and
-b proteins (50 ng/100 ll) (Deisenhofen, Germany) were utilized to
detect the expression of TNFR-I and II on cells or the ligands bind on
the receptors, respectively. Anti-mouse IgG conjugated FITC for
TNFR-I and II antibodies (DAKO Diagnostica, Hamburg, Germany)
or FITC-conjugated anti-mouse IgG for TNF-a and -b proteins were
used in the dilution of 1:100. For negative controls, the primary an-
tibodies were replaced with 1 PBS under the same condition. In all
cases, samples were placed in FACScan ﬂow cytometer (Becton
Dickinson) and 10 000 events were acquired and analyzed with the
LYSIS II software (Lysis, Mountainview, CA) and WinMDI software.
These experiments were repeated on cells ﬁxed in 4% paraformalde-
hyde and permeabilized in saponin (0.1% v/v in PBS-BSA). TNFR-I,
TNF-a and -b were detected with anti-human TNFR-I, TNF-a, and
TNF-bmouse IgG1 and anti-mouse IgG-FITC. TNFR-II was detected
with anti-human TNFR-II mouse IgG1 and anti-mouse IgG-rhoda-
mine (Santa Cruz, CA). Nuclei were stained with DAPI at 1 lg/ml for
3 min. The stained cells were viewed and photographed with a ﬂuo-
rescent microscope.
2.7. Immunoblot analysis
Cells were treated with IC50 concentration of SM for 16 h and
protein expression of TRADD, FADD, cytochrome c, Bcl-xL and
Bcl-2, caspase-3 were determined by immunoblot analysis. Cells
(1 106) were lysed at 4 C in 400 ll of lysis buﬀer (50 mM HEPES,
pH 7.4, 100 mM NaCl, 10% glycerol, 1% Nonidet P-40, 100 mM
sodium ﬂuoride and 5 mM EDTA) and protease inhibitor mix
Complete (Boehringer Mannheim). The lyses were centrifuged to
remove cellular debris. Protein concentration of the extracts was
determined using an ESL protein assay (Boehringer Mannheim) with
bovine serum albumin (BSA) as standard. Cell lysates (50 lg) were
fractionated on a 12% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) and transferred onto PVDF membrane
(Millipore, Bedford, MA). After blocking with 5% skimmed milk, the
membranes were probed with secondary antibodies (1 lg/ml) (Santa
Cruz Biotech, CA), respectively. The membranes were incubated with
protein G conjugated horseradish peroxidase (Bio-Rad, Hercules,
CA) in 1:3000 dilutions for 1 h, and subjected to ECL detection
(Amersham, Piscataway, NJ) and autoradiography by standard
procedures.
2.8. Analysis of DNA fragmentation
The cells were treated with or without IC80 concentration of SM for
16 h. Cells were collected and suspended in denaturing solution (10
mM Tris–HCl, ph 8.0, 100 mM NaCL, 25 mM EDTA, pH 8.0 and 100
lg/ml of Proteinase K) and incubated at 50 C for 12–18 h. Total DNA
was isolated by phenol/chloroform extraction and ethanol precipita-
tion, and then solubilized in TE buﬀer (10 mM Tris–HCl and 100 lM
EDTA, pH 8.0). Ten micrograms of the collected DNA was electro-
phoresed on a 1.5% agarose gel, stained with ethidium bromide and
then visualized under UV illumination.
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3.1. Comparison of the cytotoxicity of SM with
other anticancer drugs
The molecular weight of SM is 828 Da [13]. The cytotoxicity
of SM as well as conventional chemotherapeutic agents, e.g.,
paclitaxel, cisplatin, etoposide and gemcitabine were evaluated
in human lung cancer cells (H441, H520, H661 and H69).
These agents were freshly prepared and diluted with cultural
medium, and the half-inhibitory concentrations (IC50), of the
cell viability were determined by MTS method. As shown in
Fig. 1, SM inhibited cell growth in a dose-dependent manner.
The (IC50)s of SM, paclitaxel, cisplatin, etoposide and gem-
citabine were approximately 3, 45, >250, >250 and >250 lM
for H441, 6.7, 21, >250, >250 and >250 lM for H520, 7.2,
23.4, 136, >250 and >250 lM for H661, and 5.8, 22.4, 240,
>250 and >250 lM for H69 cells. The (IC80)s of SM were
approximately 11.8 lM for H441, 12.5 lM for H520, H661
and H69. Clear diﬀerences were observed in the susceptibility
of the drugs for lung cancer cells. SM is the most sensitive
agent among these cancer drugs in all lung cancer cell lines.
The lung cancer cells seem to be resistant to cisplatin, etopo-
side and gemcitabine (>50-fold IC50 of SM).
3.2. SM induces apoptosis in lung cancer cells
Translocation of membrane PS and sub-G1 fraction were
the hallmarks of apoptosis [21]. As shown in Fig. 2A, treat-
ment of cells with SM rapidly induced apoptosis in a dose- and
time-dependent manner, as demonstrated by an increasing
percentage of annexin-positive and PI-negative apoptotic cells.
Moreover, the annexin-positive cells became smaller in size
than annexin-negative cells, as shown in Fig. 2B. During in-
cubation, only few double-positive necrosis cells were detected
(less than 1% was observed). The similar results were observedC
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Fig. 1. Cytotoxicity of SM, paclitaxel, cisplatin, etopopside and gemcitabine t
was determined by MTS as described in Section 2. d, SM; s, cisplatin; .,
meanS.D. of the percentage of proliferation of the treated/untreated cellsin Fig. 3. The PI-stained apoptotic cells were analyzed by ﬂow
cytometry and most of the apoptotic cells were detected within
2 h. A 5- to 40-fold increase in the sub-G1 fraction of apop-
totic cells was detected from SM-treated cells as compared
with control. Thus, SM could induce early stage of apoptosis
in the ﬁrst hour of incubation and markedly induce cell
shrinkage and apoptosis after 3 h.
3.3. Regulation of TNFR-I and TNFR-II expression by SM
TNFRs have been involved in the process of apoptosis. The
expression of TNFRs is quenched during the progress of hu-
man lung carcinogenesis [9,10]. The gene expression of
TNFRs was determined by RT-PCR. As shown in Fig. 4A,
SM upregulated the gene expression of TNFR-I and TNFR-II
in SM (IC50 concentration)-treated cells. Besides, the results
had been veriﬁed by TNFR-I and -II antibodies to the re-
ceptors or TNF-a and -b ligands on SM-treated cells by
ﬂuorescent immunocytochemistry (Figs. 4B and 5A) and ﬂow
cytometry (Figs. 4C and 5B). These data revealed that SM
could modulate the expression of TNFRs, thereby increased
the binding activities of TNFs to TNFRs. Moreover, the
combined actions of SM and TNFs were carried out. As
shown in Figs. 6 and 7, all of these lung cancer cells were not
sensitive to TNF-a or -b. However, the increasing-growth in-
hibition of TNFs to TNF-resistant cells was observed after
SM pre-incubation. Thus, SM increased the expression of
TNFRs and consequently improved the susceptibility of lung
cancer cells to TNF-a and -b.
3.4. Apoptotic signaling cascades of SM-treated lung cancer
cells
To clarify the molecule(s) involved in SM-induced apoptotic
signal, commercial RT-PCR and synthetic primers were uti-
lized to detect apoptotic-related genes in lung cancer cells. As0 50 100 150 200 250
ntration (µM)
H661
H69
o human lung cancer (H441, H520, H661 and H69) cells. Cell viability
gemcitabine; ,, paclitaxel and j, etoposide. Each datum represents
from quaternary determinations.
Fig. 2. Two-color ﬂow cytometry analysis of lung cancer cells after staining with ﬂuorescence-labeled annexin-V and PI. (A) Apoptotic analysis of
target cells by annexin-V and PI stains in logarithmic scales. (B) Determination of the size of annexin-positive stain cells by annexin-V and forward
scatter analysis. The percentage indicates the apoptotic cell population calculated by WinMDI software. The results are shown from a representative
experiment of four independent experiments.
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Fig. 3. Sub-G1 analysis of SM-treated lung cancer cells. The percentage of SM (IC50 and IC80)-induced apoptosis was determined by ﬂow cytometry
analysis of PI-stained nuclei. Sub-G1 DNA content refers to the portion of apoptotic cells, as described in Section 2. Results depicted represent a
mean of three independent experiments in which the SD was 6 10%.
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TRADD and FADD were involved in the action mechanism
of SM. The apoptotic TRADD, FADD genes were upregu-
lated and the anti-apoptotic Bcl-xL and Bcl-2 genes were
downregulated after the IC50 concentration of SM treatment
for 16 h. The similar results were observed by Western blotting
(Figs. 8B and 9B). Alternately, SM caused the release of cy-
tochrome c from mitochondria. Induction of apoptosis by SMin lung cancers was accompanied by signiﬁcant increase in
caspase-3 activity (Fig. 9B). At the late phase of apoptosis, the
activation of caspase-3 will cleave DNA into oligonucleosomal
fragments (180–200 bp). As shown in Fig. 8C, when the cells
were treated with IC80 concentration of SM for 24 h, a DNA
ladder was appeared. The results revealed that TNFR and Bcl-
2 signaling pathway might be involved in SM-induced apop-
tosis of lung cancers.
Fig. 5. Determination of TNF-a and -b binding on human lung cancer cells after SM treatment. The cells were treated with or without IC50 con-
centration of SM. The binding activities of TNF-a and -b were studied by ﬂuorescent immunocytochemistry (A) and ﬂow cytometry (B) as described
in Section 2.
Fig. 4. Regulation of TNFR-I and TNFR-II expression in human lung cancer cells after SM treatment. The cells were treated with or without IC50
concentration of SM. The expressions of TNFR-I and -II were studied by RT-PCR (A), ﬂuorescent immunocytochemistry (B) and ﬂow cytometry
(C) as described in Section 2.
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Fig. 7. Eﬀect of human TNF-b on the cytotoxicity of lung cancer cells after SM (IC25 and IC50) treatment. Cell viability was determined by MTS
assay. Each datum represent means S.D. of the percentage of proliferation of the TNF-b treated/untreated cells from quaternary determinations.
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Fig. 6. Eﬀect of human TNF-a on the cytotoxicity of lung cancer cells after SM (IC25 and IC50) treatment. Cell viability was determined by MTS
assay. Each datum represents mean S.D. of the percentage of proliferation of the TNF-a treated/untreated cells from quaternary determinations.
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Approaches utilizing combinations of chemotherapeutic,
radiation and/or surgical modalities are the standard of care
for treating lung cancers. Several new anticancer agents have
been developed, including paclitaxel, docetaxel, vinorelbine,gemcitabine, camptothecines, irinotecan and topotecan in the
treatment of lung cancers [22]. Although these drugs may be
eﬀective in lung cancers, identifying new drugs to improve the
currently dismal survival rates in lung cancer patients is im-
portant. Chinese herbs are composed of active components
that exhibit the capability of regulating cell activities. Previous
Fig. 9. RT-PCR andWestern blot of the apoptotic gene expression and
DNA fragmentation of SM-treated lung cancer cells. Cells were treated
with SM (IC50 concentration) for 16 h. The changes of cytochrome c,
Bcl-xL, Bcl-2 and caspase-3 expressions were analyzed by RT-PCR (A)
and by immunoblotting (B). Arrows indicate the genes involved in the
signal cascade of SM-induced apoptosis. (C) DNA ladder of the cells
treated with IC80 concentration of SM for 24 h as described in Section 2.
Fig. 8. Regulation of TRADD and FADD expression in human lung
cancer cells after SM treatment. The cells were treated with or without
IC50 concentration of SM. The expressions of TRADD, FADD and b-
actin genes were studied by RT-PCR (A) and Western blots (B). Cell
lysates (25 lg/land) were separated by a 12% SDS–PAGE, and
TRADD and FADD were monitored by immunoblotting as described
in Section 2.
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theoretical [23]. In order to identify active components from
Chinese herbs, many pure compounds have been puriﬁed from
Chinese herbs. However, the detailed action mechanisms of the
compounds have not been well conducted. This paper illus-
trated the action mechanism of SM in human lung cancer cells.
Compared with the relative sensitivity of cells to paclitaxel,
cisplatin, gemcitabine and etoposide, SM has shown a superior
eﬀect in human lung cancer cells.
Apoptosis is a genetically encoded and tightly regulated
‘suicidal’ process in which the cell actively participates in its
own destruction. Under the microscopic examination, SM-
treated cells initially became round in shape, subsequently lost
contact with neighboring cells, and ﬁnally ﬂoated into me-
dium. After 16 h of incubation with SM, the cytoplasmic
shrinking, phosphatidylserine externalization, chromatin con-
densation and numerous apoptotic bodies were found in the
apoptotic cells (the data observed form microscopy was not
shown). The action of SM full-ﬁlled the criterions of apoptosis
in human lung cancer cells, implied that SM-induced cell death
by apoptosis. In malignant cells, the physiological apoptotic
pathways are often altered, resulting in a signiﬁcant survivaladvantage and developed resistance to anti-tumor treatments
[24]. A loss of TNF receptors expression was found in ad-
vanced lung cancers, suggesting downregulation of TNFRs in
the process of tumor progression [9,10]. In the present data,
SM could elevate the gene and protein expressions of TNFR-I,
TNFR-II, and the downstream signaling cascades of TRADD
and FADD in human lung cancer cells. We also had demon-
strated that SM could induce programmed cell death by up-
regulated TNFRs in Hep 3B [17]. Thus, activation of TNFRs
might be one of the important roles involved in the action
mechanism of SM.
TNF has shown an antiproliferative eﬀect against various
NSCLC cell lines in vitro and in vivo, but the clinical trails
with TNF in combination with other cytokines have demon-
strated both conﬂicting and disappointing results [10,25,26]. In
this study, the binding of TNF-a and TNF-b to TNFRs was
increased in SM-treated cells by ﬂuorescent immunocyto-
chemistry and ﬂow cytometry assay. Also, SM might via up-
modulation of TNFRs sensitize TNF-resistance lung cancer
cells to TNFs, as revealed by growth-inhibition assay. How-
ever, the concentration of secreted TNFs was not signiﬁcantly
increased in the SM-treated medium by ELISA assay (data not
shown). A similar result has been reported that retinoic acid
would modulate the expression of TNFR-I and TNFR-II in
lung cancer cells and sensitize cells to TNF-induced apoptosis
[11]. These ﬁndings indicate that activation of TNFR signal
transduction may be a new focus to investigate a drug for
treating lung cancers.
It had been reported that overexpression of anti-apoptotic
protein Bcl-xL and Bcl-2 may increase apoptotic resistance and
correlate with the multidrug resistance of lung cancers [27]. The
antisense oligonucleotides of Bcl-2 and Bcl-xL have been used in
treatment or combination of anti-cancer drugs for induction of
apoptosis in lung cancer cells [28–32]. Several mechanisms have
been implicated in TNF resistance, one of which is to alter the
expression of oncogenes (e.g., bcl-2) that subsequently activate
anti-apoptotic pathways may also contribute to the resistance
phenotype [33,34]. Interestingly, a decreased expression of Bcl-
xL and Bcl-2 was observed in SM-treated lung cancer cells.
Thus, the enhanced susceptibility of lung cancer cells to TNFs
may be correlated with the up-modulation of TNFRs, but also
the down-regulation of Bcl-2 expression by SM.
Activation of caspases may be the ultimate eﬀectors mech-
anism in apoptotic pathways. Caspase-3 is associated with
drug-induced apoptosis in lung cancer cell lines and is required
for DNA fragmentation [35]. The activation of caspase-3 was
observed in SM-treated cells, and resulted in cell shrinkage,
DNA ladder and sub-G1 peak. Anticancer drugs may exert
both Fas receptor and ligand to trigger apoptosis. But, the
apoptosis induced by chemotherapeutic agents is not mediated
through Fas/FasL (CD95/APO1) signaling pathway in many
lung cancers patients [36]. In our experiment, the expression of
Fas was not involved in SM-induced apoptosis of lung cancer
cells (data not shown). Subsequent study revealed that SM
could cause release of cytochrome c in lung cancer cells. In-
sight regarding the proteins that determine sensitivity for
chemotherapeutic drugs could provide new targets for cancer
treatment, which may help to at least partly overcome drug
resistance in lung cancers. Our results suggest that TNFR and
mitochondria signal pathway might mediate the anti cancer
eﬀects of SM. This paper illustrates that SM may be a superior
agent for the treatment of lung cancers.
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